Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy

Cancers(2022)10.3390/cancers14092220Source: DataRank Database

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0.753. It has been cited 150 times.

N/A

0.753DataRank · unranked

Scored on demand from live citation data

Open Access150 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (9)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.753

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (6)

Annabel M. McAtee ORCID,Khaga R. Neupane,Christopher I. Richards ORCID,Frederick R. Ueland ORCID,Jill Kolesar ORCID

Live enrichment

PubMed:35565348 PMC:PMC9101750

NIH Training Grant

Grant: T32CA160003

NIH Training Grant

Grant: P30 CA177558

National Institutes of Health

Grant: 5T32CA160003-03

Oncology Research Training for Surgeon-Scientists

National Institutes of Health

Grant: 3P30CA177558-01S1

CTRP Supplement

goldLicense: CC BY

publisherhttps://www.mdpi.com/2072-6694/14/9/2220/pdf

Unpaywallhttps://www.mdpi.com/2072-6694/14/9/2220/pdf?version=1651209611

Europe_PMChttps://europepmc.org/articles/PMC9101750

Europe_PMChttps://europepmc.org/articles/PMC9101750?pdf=render

https://doi.org/10.3390/cancers14092220

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

Keywords

MacrophagesImmunotherapyOvarian cancerTAMRepolarizationReview

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665122.v1figshare

Additional file 1 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665122figshare

Additional file 2 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665125.v1figshare

Additional file 2 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665125figshare

Additional file 3 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665128.v1figshare

Additional file 3 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665128figshare

Additional file 4 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665131.v1figshare

Additional file 4 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665131figshare

Additional file 5 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665134.v1figshare

Additional file 5 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665134figshare

Additional file 6 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665137.v1figshare

Additional file 6 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665137figshare

Additional file 7 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665140.v1figshare

Additional file 7 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665140figshare

Additional file 8 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665143figshare

Additional file 8 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665143.v1figshare

Additional file 9 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665149.v1figshare

Additional file 9 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665149figshare

Additional file 10 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665152.v1figshare

Additional file 10 of Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy

10.6084/m9.figshare.23665152figshare